Claims for Patent: 6,977,165

Summary for Patent: 6,977,165

Title:	Sequence specific recombinase-based methods for producing intron containing vectors and compositions for use in practicing the same
Abstract:	Methods are provided for producing a vector that includes at least one splicable intron. In the subject methods, intron containing vectors are produced from donor and acceptor vectors that each include a site specific recombinase site, where the subject donor and acceptor vectors further include splice donor and acceptor sites that, upon site specific recombination of the donor and acceptor vectors, define an intron in the product vector of the recombination step. Also provided are compositions for use in practicing the subject methods, including the donor and acceptor vectors themselves, as well as systems and kits that include the same. The subject invention finds use in a variety of different applications, including the production of expression vectors that encode C-terminal tagged fusion proteins, the production of expression vectors that encode pure protein and not a fusion thereof, and the like.
Inventor(s):	Farmer; Andrew Alan (Mountain View, CA)
Assignee:		Clontech Laboratories, Inc. (Mountain View, CA)
Application Number:	10/055,794
Patent Claims:	1. A composition for use in preparing an intron containing vector, said composition comprising: a donor vector comprising at least one splice site and an acceptor vector comprising at least one splice site, wherein said donor and acceptor vectors each comprise at least one sequence-specific recombinase target site and wherein one of said donor and acceptor vectors comprises two sequence-specific recombinase target sites and the other of said donor and acceptor vectors comprises a single sequence-specific recombinase target site, wherein all of said sequence-specific recombinase target sites are able to recombine with each other. 2. The composition according to claim 1, wherein said donor vector comprises two sequence-specific recombinase target sites and said acceptor vector comprises a single sequence-specific recombinase target site. 3. The composition according to claim 2, wherein said two sequence-specific recombinase target sites on said donor vector are oriented in the same direction. 4. The composition according to claim 1, wherein said donor vector comprises a single sequence-specific recombinase target site and said acceptor comprises two sequence-specific recombinase target sites. 5. The composition according to claim 4, wherein said two sequence-specific recombinase target sites of said acceptor vector are oriented in the same direction. 6. The composition according to claim 1, wherein said system further comprises a sequence specific recombinase. 7. The composition according to claim 1, wherein said sequence-specific recombinase target sites are selected from the group consisting of: lox sites, att sites, dif sites and frt sites. 8. The composition according to claim 1, wherein said donor and acceptor vectors are plasmids, cosmids, bacs, yacs or viruses. 9. The composition according to claim 1 wherein said composition has been inserted. 10. The composition according to claim 1, wherein said at least one splice site in each of said donor and acceptor vectors comprises a splice donor and a splice acceptor sequence. 11. A kit for use in a producing an expression vector, said kit comprises: (a) a donor vector comprising a splice site; and (b) an acceptor vector comprising a splice site; wherein each of said donor and acceptor vectors further comprises at least one sequence-specific recombinase target site and wherein one of said donor and acceptor vectors comprises two sequence-specific recombinase target sites and the other of said donor and acceptor vectors comprises a single sequence-specific recombinase target site, wherein all of said sequence-specific recombinase target sites are able to recombine with each other. 12. The kit according to claim 11, wherein said kit further comprises a sequence specific recombinase that recognizes said sequence-specific recombinase target sites. 13. A method of producing an intron containing vector, said method comprising: combining a splice site comprising donor vector and a splice sequence comprising acceptor vector, wherein one of said donor and acceptor vectors comprises two sequence-specific recombinase target sites and the other of said donor and acceptor vectors comprises a single sequence-specific recombinase target site, wherein all of said sequence-specific recombinase target sites are able to recombine with each other, with a recombinase under conditions sufficient for site-specific recombination to occur to produce said intron containing vector. 14. The method according to claim 13, wherein said donor vector comprises two sequence-specific recombinase target sites and said acceptor vector comprises a single sequence-specific recombinase target site. 15. The method according to claim 13, wherein said donor vector comprises a single sequence-specific recombinase target site and said acceptor vector comprises two sequence-specific recombinase target sites. 16. The method according to claim 13, wherein said sequence specific recombinase is selected from the group consisting of: recombinases, transposases and integrases. 17. The method according to claim 13, wherein said sequence specific recombinase is Cre recombinase. 18. The method according to claim 13, wherein said sequence-specific recombinase target sites are selected from the group consisting of: lox sites, att sites, dif sites and frt sites. 19. The method according to claim 18, wherein said recombinase recognition sites are lox sites.

Details for Patent 6,977,165

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-01-18